Page 38 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

Table 7. Summary of the representative antioxidant nanomedicines for the treatment of ocular diseases
Antioxidant nanomedicine Reaction type Disease References
Poly (catechin)-containing nanomedicine Non-catalytic AMD 362
Resveratrol-loading polycaprolactone nanoparticle Non-catalytic AMD 363
CeO nanoparticle Catalytic AMD 364-366
2
Melanin nanoparticle Non-catalytic AMD 369
Pt nanoparticle-loading liposome Catalytic Retinal neovascularization 379
Single-atom iron nanocatalyst with defective Fe–N sites Catalytic Retinal neovascularization 380
4
Chitosan-modified CeO nanoparticle Catalytic Glaucoma 386
2
Abbreviation: AMD: Age-related macular degeneration

Figure 25. Schematic illustration for the construction of single-atom iron nanocatalyst with defective Fe–N sites, as well as its application in treating
4
retinal neovascularization. Reproduced with permission from Zhang et al. Copyright © 2022, Wiley-VCH.
380
and adalimumab have been applied in clinic for treating cannot scavenge ROS, and their side effects are prominent.
inflammatory bowel disease; 393,394 however, these drugs Antioxidants such as Vitamin C, Vitamin E, and coenzyme

Volume 1 Issue 1 (2024) 32 doi: 10.36922/imo.2527